ArticleLeukemia2015
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.
Abstract readLetter
In one paragraph
Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.International journal of hematology · 2015Pooled it
- Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.Leukemia · 2026Review
- Mutational landscape of classical myeloproliferative neoplasms in the Western Cape Province, South Africa.African journal of laboratory medicine · 2026Article
- Review
- Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China.Annals of hematology · 2023Article
- Mutation-Driven S100A8 Overexpression Confers Aberrant Phenotypes in Type 1International journal of molecular sciences · 2023Article
- CALR type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients.Irish journal of medical science · 2023Article
- Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology.Cells · 2023Review
- Structural and Dynamic Differences between Calreticulin Mutants Associated with Essential Thrombocythemia.Biomolecules · 2023Article
- Review
- Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.Annals of hematology · 2022Article
- Effects ofDiagnostics (Basel, Switzerland) · 2022Article
- Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.International journal of molecular sciences · 2022Review
- Review
- Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms.Cells · 2021Review
- Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics.Cancers · 2021Review
- Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms.HemaSphere · 2021Article
- Disease modifying agents of myeloproliferative neoplasms: a review.Blood research · 2021Review
- The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.International journal of molecular sciences · 2021Review
- A Broad Overview of Signaling inCancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
X Cabagnols1] UMR 1009 INSERM, Laboratory of Excellence GR-Ex, Villejuif, France [2] Gustave Roussy, UMR 1009, Villejuif, France [3] Université Paris-Sud, UMR 1009, Villejuif, France.
J P Defour1] Ludwig Institute for Cancer Research, Brussels, Belgium [2] de Duve Institute, Université catholique de Louvain, Brussels, Belgium [3] Department of Clinical Biology, Cliniques universitaires St Luc, Brussels, Belgium.
V Ugo1] CHU de Brest, Laboratoire d'Hématologie, Brest, France [2] Université de Brest, Faculté de Médecine, Université Européenne de Bretagne, Brest, France [3] INSERM U1078, Brest, France.
J C IanottoCHU de Brest, Laboratoire d'Hématologie, Brest, France.
P MossuzUMR 5525 CNRS- équipe TheRex, Université Joseph Fourier- Grenoble-1 Grenoble, France.
J MondetUMR 5525 CNRS- équipe TheRex, Université Joseph Fourier- Grenoble-1 Grenoble, France.
F Girodon1] Laboratoire d'Hématologie, CHU de Dijon, Dijon, France [2] INSERM U866, Faculté de Médecine, Dijon, France.
J H AlexandreLaboratoire d'Hématologie, CHU de Dijon, Dijon, France.
O MansierLaboratoire d'Hématologie, CHU de Bordeaux et Laboratoire Hématopoïèse Leucémique et Cibles Thérapeutiques, INSERM U1035, Université de Bordeaux, Bordeaux, France.
J F ViallardService de Médecine Interne et Maladies Infectieuses, Hôpital Haut-Lévêque, CHU de Bordeaux, Bordeaux, France.
E LippertLaboratoire d'Hématologie, CHU de Bordeaux et Laboratoire Hématopoïèse Leucémique et Cibles Thérapeutiques, INSERM U1035, Université de Bordeaux, Bordeaux, France.
A MuratiDépartement de Biopathologie et d'Oncologie Moléculaire, Institut Paoli-Calmettes, Marseille, France.
M J MozziconacciDépartement de Biopathologie et d'Oncologie Moléculaire, Institut Paoli-Calmettes, Marseille, France.
P SaussoyDepartment of Clinical Biology, Cliniques universitaires St Luc, Brussels, Belgium.
M C VekemansDepartment of Hematology, Cliniques universitaires St Luc, Brussels, Belgium.
L Knoopsde Duve Institute, Université catholique de Louvain, Brussels, Belgium.
F Pasquier1] UMR 1009 INSERM, Laboratory of Excellence GR-Ex, Villejuif, France [2] Gustave Roussy, UMR 1009, Villejuif, France [3] Université Paris-Sud, UMR 1009, Villejuif, France.
V Ribrag1] UMR 1009 INSERM, Laboratory of Excellence GR-Ex, Villejuif, France [2] Gustave Roussy, UMR 1009, Villejuif, France [3] Université Paris-Sud, UMR 1009, Villejuif, France.
E Solary1] UMR 1009 INSERM, Laboratory of Excellence GR-Ex, Villejuif, France [2] Gustave Roussy, UMR 1009, Villejuif, France [3] Université Paris-Sud, UMR 1009, Villejuif, France.
I Plo1] UMR 1009 INSERM, Laboratory of Excellence GR-Ex, Villejuif, France [2] Gustave Roussy, UMR 1009, Villejuif, France [3] Université Paris-Sud, UMR 1009, Villejuif, France.
S N Constantinescu1] Ludwig Institute for Cancer Research, Brussels, Belgium [2] de Duve Institute, Université catholique de Louvain, Brussels, Belgium.
N Casadevall1] UMR 1009 INSERM, Laboratory of Excellence GR-Ex, Villejuif, France [2] Gustave Roussy, UMR 1009, Villejuif, France [3] AP-HP, Hôpital Saint-Antoine, Laboratoire d'Hématologie, Paris, France.
W Vainchenker1] UMR 1009 INSERM, Laboratory of Excellence GR-Ex, Villejuif, France [2] Gustave Roussy, UMR 1009, Villejuif, France [3] Université Paris-Sud, UMR 1009, Villejuif, France.
C Marzac1] AP-HP, Hôpital Saint-Antoine, Laboratoire d'Hématologie, Paris, France [2] Sorbonne Universités, UPMC Univ Paris 06, GRC n°07, Groupe de Recherche Clinique sur les Myéloproliférations Aiguës et Chroniques MyPAC, Paris, France [3] INSERM, UMR_S 938, CDR Saint-Antoine, Paris, France.
O Bluteau1] UMR 1009 INSERM, Laboratory of Excellence GR-Ex, Villejuif, France [2] Gustave Roussy, UMR 1009, Villejuif, France [3] Université Paris-Sud, UMR 1009, Villejuif, France.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAdolescentAdultAgedAged, 80 and overCalreticulinChildFemaleHumansMaleMiddle AgedPrimary MyelofibrosisProtein IsoformsThrombocythemia, EssentialYoung AdultCalreticulinProtein Isoforms
Identifiers
PMID
25212275What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.